Q1 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Syndax Pharmaceuticals Inc (SNDX) reported strong financial performance with $20 million in net revenue from Revvvi Forge and $13.6 million from Nick Timbo in the first quarter of 2025.
- The company has a robust pipeline with ongoing clinical trials, including the initiation of the Evolve II trial for Revvvi Forge, targeting a high unmet medical need in AML patients.
- Syndax Pharmaceuticals Inc (SNDX) is well-funded with $602.1 million in cash and equivalents, supporting its strategic initiatives and potential market expansions.
- The company has achieved significant milestones, including the submission of a supplemental new drug application (SNDA) for Revvvi Forge, seeking priority review for the treatment of relapse or refractory mutant NPM1 AML.
- Strong market access and formulary coverage for Revvvi Forge, with approximately 72% of managed care lives covered, facilitating quick patient access to the medication.
- The company faces challenges in accurately estimating the total addressable market for its products, as the actual patient population may differ from initial projections.
- There is limited data on the long-term duration of therapy and refill dynamics for Revvvi Forge, making it difficult to predict future revenue streams accurately.
- Syndax Pharmaceuticals Inc (SNDX) is still in the early stages of collecting real-world evidence for its products, which may impact the ability to provide detailed insights into patient outcomes and treatment patterns.
- The company has not yet provided specific details on the powering of its Evolve II trial, which could affect investor confidence in the trial's potential success.
- Reimbursement for post-transplant use of Revvvi Forge remains uncertain, which could impact the drug's adoption and revenue potential in this setting.
Good day, everyone, and welcome to the Syndax first-quarter 2025 earnings conference call. Today's call is being recorded. (Operator Instructions)
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Great. Thank you, operator. Welcome and thank you all for joining us today for a review of Syndax's first-quarter 2025 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; Steve Closter, Chief Commercial Officer; and Keith Goldan, Chief Financial Officer.
Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Strategy Officer.
This call is accompanied by a slide deck that has been posted on the Investor page
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
